Pentokey Organy (India) Limited appointed Ms. Kavita Kailash Bohra as an additional non-executive independent director on August 13, 2026. The Board of Directors approved the move during its meeting held on the same date, effective immediately for a five-year term. The appointment remains subject to shareholder approval.

The Nomination and Remuneration Committee recommended Ms. Bohra’s appointment. She holds DIN 11003259 and is not debarred from holding office by SEBI, the Ministry of Corporate Affairs, or any other statutory authority. She is unrelated to any existing directors of the company.

Director Profile

Ms. Bohra is a Fellow Member of the Institute of Chartered Accountants of India (ICAI) with a Certificate of Practice obtained in 2018. She brings over eight years of post-qualification experience in audit, assurance, corporate governance, and regulatory compliance.

Her professional background includes extensive involvement in financial reporting, statutory and internal audits, risk management, and compliance advisory. She has advised organizations on regulatory compliance, financial structuring, and risk migration strategies under the Companies Act, 2013 and allied laws.

Key Details

The company made the disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015.

Pentokey Organy (India) Limited reported a net profit of ₹21.73 lakh for the quarter ended June 30, 2026, marking a significant decline from the ₹48.47 lakh posted in the corresponding period of FY25. The Mumbai-based pharma and pesticides trading firm recorded zero revenue from operations for the quarter, a sharp contrast to the ₹506.20 lakh generated in Q1FY26.

The Board of Directors approved the unaudited financial results in a meeting held on August 13, 2026. The figures were reviewed by the Audit Committee and subsequently approved by the Board, which convened from 12:30 pm to 1:10 pm.

Financial Performance

Despite the absence of operational revenue, the company remained profitable due to other income and lower expenses compared to the prior year. Other income stood at ₹8.34 lakh, up from ₹4.00 lakh in Q1FY25. Total expenses for the quarter were negative ₹13.39 lakh, primarily driven by a credit entry of ₹17.69 lakh under "Others Expenses," offset by employee benefit expenses of ₹4.30 lakh.

For the full year ended March 31, 2026, Pentokey Organy reported a net profit of ₹20.32 lakh on total income of ₹249.80 lakh, compared to a profit of ₹24.55 lakh on income of ₹129.05 lakh in FY25.

What the Numbers Show

The divergence between revenue and profitability highlights a structural shift in the company's earnings mix for the quarter. With revenue from operations at zero, other income accounted for 100% of the top-line inflow, while the negative expense figure suggests significant non-cash credits or reversals in the "Others Expenses" category. This indicates that the reported net profit is not derived from core trading activities in the pharma/pesticides segment but rather from incidental gains and expense adjustments.

Auditor Review

Verma Mehta & Associates, the statutory auditors, issued an unmodified review report on the interim financial results. The audit firm stated that nothing came to their attention to cause them to believe the statement had not been prepared in accordance with Ind AS and SEBI Listing Regulations. The results have been prepared in compliance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013.